Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.45 |
| ▸ | CASP1 | P29466 | 3/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CASP7 | P55210 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4311048 | 0.89 | SCD (0.51) | SCDALDH1A1CYP1A2CASP1HSD17B10 | |
| SCHEMBL4311710 | 0.78 | AKR1B10 (0.49) | — | |
| SCHEMBL4312658 | 0.77 | PDE3B (0.45) | ALDH1A1CYP1A2CYP3A4CYP2C9HPGD | |
| SCHEMBL4311696 | 0.76 | CCR9 (0.48) | SCDALDH1A1CYP1A2CASP1HSD17B10 | |
| SCHEMBL4312795 | 0.76 | SCD (0.43) | SCD | |
| SCHEMBL28430136 | 0.75 | CFTR (0.57) | ALDH1A1CYP1A2CASP1HSD17B10USP2 | |
| SCHEMBL29388744 | 0.75 | CFTR (0.57) | ALDH1A1CYP1A2CASP1HSD17B10USP2 | |
| SCHEMBL17184347 | 0.74 | CFTR (0.59) | SCDALDH1A1CYP1A2USP2CYP3A4 | |
| SCHEMBL28433786 | 0.74 | CFTR (0.55) | ALDH1A1CYP1A2CASP1HSD17B10USP2 | |
| SCHEMBL29386548 | 0.74 | CFTR (0.55) | ALDH1A1CYP1A2CASP1HSD17B10USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNN3, KCNN1, KCNN2 | SCD 4403/4885ALDH1A1 1707/4885CYP1A2 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.